Nuvation Bio (NUVB) EBIT (2020 - 2026)
Nuvation Bio (NUVB) posted quarterly EBIT of $3.9 million for Q1 2026, up 106.58% year-over-year from $1.9 million in Q1 2025, and up 111.4% quarter-over-quarter from -$34.0 million in Q4 2025.
Nuvation Bio (NUVB) EBIT (2020 - 2026) Analysis & Trends
Nuvation Bio (NUVB) has reported EBIT for 7 consecutive years, with $3.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBIT rose 106.58% year-over-year to $3.9 million; the TTM figure through Mar 2026 stood at -$150.2 million (up 76.22% YoY), while the FY2025 annual figure was -$213.1 million, up 64.05% from the prior year.
- EBIT improved to $3.9 million in Q1 2026 per NUVB's latest filing, from -$34.0 million in the prior quarter.
- Across five years, EBIT topped out at $3.9 million in Q1 2026 and bottomed at -$470.4 million in Q2 2024.
- Historically, EBIT has averaged -$60.1 million across 5 years, with a median of -$29.3 million in 2022.
- Annual changes were most pronounced in 2024 — EBIT sank 1700.1% — and 2026, when it surged 106.58%.
- Nuvation Bio's EBIT stood at -$24.3 million in 2022, then gained by 14.4% to -$20.8 million in 2023, then tumbled by 158.95% to -$53.9 million in 2024, then soared by 36.9% to -$34.0 million in 2025, then soared by 111.4% to $3.9 million in 2026.
- Business Quant data shows NUVB's EBIT at $3.9 million in Q1 2026, -$34.0 million in Q4 2025, and -$56.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Nuvation Bio | 2.16 Bn | 2.16 Bn | 30.78 Mn | -51.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -51.04 Mn |
| Mar 31, 2026 | 3.88 Mn |
| Dec 31, 2025 | -34.04 Mn |
| Sep 30, 2025 | -56.43 Mn |
| Jun 30, 2025 | -63.59 Mn |
| Mar 31, 2025 | -59.00 Mn |
| Dec 31, 2024 | -53.94 Mn |
| Sep 30, 2024 | -48.10 Mn |
| Jun 30, 2024 | -470.39 Mn |
| Mar 31, 2024 | -20.20 Mn |
| Dec 31, 2023 | -20.83 Mn |
| Sep 30, 2023 | -26.34 Mn |
| Jun 30, 2023 | -26.13 Mn |
| Mar 31, 2023 | -26.52 Mn |
| Dec 31, 2022 | -24.34 Mn |
| Sep 30, 2022 | -29.34 Mn |
| Jun 30, 2022 | -37.87 Mn |
| Mar 31, 2022 | -28.19 Mn |
| Dec 31, 2021 | -29.61 Mn |
| Sep 30, 2021 | -22.79 Mn |